Emory University School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (51)

2024

  1. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682

  2. Effect of an intensive lifestyle intervention on the structural and functional substrate for atrial fibrillation in people with metabolic syndrome

    European Journal of Preventive Cardiology, Vol. 31, Núm. 5, pp. 629-639

  3. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

  4. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  5. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

    Journal of Hepatology

  6. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  7. KDM6A regulates immune response genes in multiple myeloma

    Blood, Vol. 144, Núm. 14, pp. 1508-1520

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

    FASEB Journal, Vol. 37, Núm. 11

  3. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

    Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

    JACC: Cardiovascular Imaging, Vol. 15, Núm. 11, pp. 1883-1896

2021

  1. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154

  2. Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C

    Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674

  3. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

    Nature Genetics, Vol. 53, Núm. 9, pp. 1311-1321

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  6. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 5, pp. 1570-1584

  7. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

  8. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212